文献速递血栓与止血

血管性血友病因子-ADAMTS-13轴对未来静脉血栓栓塞风险的影响

Impact of the von Willebrand factor-ADAMTS-13 axis on the risk of future venous thromboembolism.
PubMed 文献 · J Thromb Haemost · 2023-02-01

基于特罗姆瑟研究队列(1994-2007)的巢式病例对照研究,纳入383例新发静脉血栓栓塞病例和780例年龄性别匹配对照,检测基线血浆ADAMTS-13和血管性血友病因子抗原水平。ADAMTS-13最低与最高四分位组对比OR为1.40(95%CI 0.99-1.99),VWF/ADAMTS-13比值最高与最低四分位组对比OR为1.70(95%CI 1.19-2.43),无诱因VTE的OR为2.81(95%CI 1.65-4.81)。

要点

  • ADAMTS-13最低与最高四分位组对比,VTE风险OR为1.40(95%CI 0.99-1.99)。
  • VWF/ADAMTS-13比值最高与最低四分位组对比,VTE风险OR为1.70(95%CI 1.19-2.43),趋势P=.001。
  • 无诱因VTE中VWF/ADAMTS-13比值最高与最低四分位组对比OR为2.81(95%CI 1.65-4.81)。

核心结论

  • ADAMTS-13水平降低及VWF/ADAMTS-13比值升高与未来VTE风险增加相关,提示VWF-ADAMTS-13轴可能参与VTE发病机制。

研究设计与样本

  • 基于特罗姆瑟研究队列(1994-2007)的巢式病例对照研究,纳入383例新发VTE病例和780例年龄性别匹配对照,检测基线血浆ADAMTS-13和VWF抗原水平。

主要发现

  • ADAMTS-13最低与最高四分位组对比,VTE风险OR为1.40(95%CI 0.99-1.99)。
  • VWF/ADAMTS-13比值与VTE风险呈线性关联(趋势P=.001),最高与最低四分位组对比OR为1.70(95%CI 1.19-2.43)。
  • 无诱因VTE中VWF/ADAMTS-13比值最高与最低四分位组对比OR为2.81(95%CI 1.65-4.81)。
  • 额外调整体重指数和C反应蛋白后OR仅轻度衰减。

关键数值与推荐

  • ADAMTS-13按对照四分位 cutoff 分组,最低与最高四分位组对比OR为1.40(95%CI 0.99-1.99)。
  • VWF/ADAMTS-13比值按对照四分位 cutoff 分组,最高与最低四分位组对比OR为1.70(95%CI 1.19-2.43),趋势P=.001。
  • 无诱因VTE中VWF/ADAMTS-13比值最高与最低四分位组对比OR为2.81(95%CI 1.65-4.81)。

临床怎么用

  • 原文结论未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: von Willebrand factor (VWF) and its cleaving protease, ADAMTS-13, form a pivotal axis that regulates hemostasis. However, the role of the VWF-ADAMTS-13 axis in the risk of future venous thromboembolism (VTE) is unknown. OBJECTIVES: To investigate whether plasma ADAMTS-13 levels and an imbalance with VWF levels, assessed as the VWF/ADAMTS-13 ratio, are associated with the risk of future VTE. PATIENTS/METHODS: A population-based nested case-control study, comprising 383 incident VTE cases and 780 age- and sex-matched controls, was derived from the Tromsø study cohort (1994-2007). Antigen levels of ADAMTS-13 and VWF were measured in plasma samples obtained at cohort baseline. Odds ratios (ORs) with 95% CIs were estimated according to quartile cutoffs of ADAMTS-13 and VWF/ADAMTS-13 ratio determined in controls. RESULTS: In age- and sex-adjusted analysis, ADAMTS-13 levels were inversely associated with the VTE risk, with an OR of 1.40 (95% CI, 0.99-1.99) for the lowest vs highest quartiles. The VWF/ADAMTS-13 ratio was linearly associated with the VTE risk (P for trend = .001), with an OR of 1.70 (95% CI, 1.19-2.43) for the highest vs lowest quartiles, and the association was particularly pronounced for unprovoked VTE (OR, 2.81; 95% CI, 1.65-4.81). The ORs were only slightly attenuated after additional adjustments for body mass index and C-reactive protein. CONCLUSIONS: Lowered ADAMTS-13 levels and an imbalance between ADAMTS-13 and VWF levels, reflected by an increased VWF/ADAMTS-13 ratio, were associated with an increased risk of future VTE. Our findings suggest that the VWF-ADAMTS-13 axis is involved in the pathogenesis of VTE.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Edvardsen MS, Hansen ES, Ueland T, et al. Impact of the von Willebrand factor-ADAMTS-13 axis on the risk of future venous thromboembolism. J Thromb Haemost. 2023. PMID: 36736832. doi:10.1016/j.jtha.2023.01.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。